KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Long-Term Deferred Tax: 2009-2010

Historic Long-Term Deferred Tax for Rigel Pharmaceuticals (RIGL) over the last 2 years, with Dec 2010 value amounting to $197.0 million.

  • Rigel Pharmaceuticals' Long-Term Deferred Tax fell 6.59% to $197.0 million in Q4 2010 from the same period last year, while for Dec 2010 it was $197.0 million, marking a year-over-year decrease of 6.59%. This contributed to the annual value of $197.0 million for FY2010, which is 6.59% down from last year.
  • Rigel Pharmaceuticals' Long-Term Deferred Tax amounted to $197.0 million in FY2010, which was down 6.59% from $210.9 million recorded in FY2009.
  • Rigel Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $210.9 million for FY2009, and its period low was $197.0 million during FY2010.
  • Moreover, its 2-year median value for Long-Term Deferred Tax was $204.0 million (2009), whereas its average is $204.0 million.
  • Data for Rigel Pharmaceuticals' Long-Term Deferred Tax shows a maximum YoY dropped of 6.59% (in 2010) over the last 5 years.
  • Yearly analysis of 2 years shows Rigel Pharmaceuticals' Long-Term Deferred Tax stood at $210.9 million in 2009, then dropped by 6.59% to $197.0 million in 2010.